文献速递类风湿关节炎

在挪威常规临床实践中接受SB4与参照依那西普治疗的类风湿关节炎患者的有效性与药物持续性

Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-03-07

该回顾性数据库研究纳入挪威5个中心2010至2018年间接受依那西普或SB4治疗且随访≥1年的1455例类风湿关节炎患者,比较第52周DAS28变化与药物持续性。非匹配分析中两组DAS28变化差值均值-0.02(95%CI -0.32, 0.27),在预设等效界值±0.6内;倾向性评分匹配分析差值为0.03(95%CI -0.46, 0.52),亦在界值内。第52周药物持续性两组相似。

要点

  • 非匹配分析中依那西普组(n=221)与SB4组(n=106)第52周DAS28变化差值均值-0.02(95%CI -0.32, 0.27),在预设等效界值±0.6内。
  • 倾向性评分匹配分析中依那西普组(n=49)与SB4组(n=49)DAS28变化差值为0.03(95%CI -0.46, 0.52),在预设等效界值内。
  • 非匹配分析第52周药物持续性依那西普组0.62(95%CI 0.57, 0.65)与SB4组0.66(95%CI 0.60, 0.71)相似;匹配队列中依那西普组0.52(95%CI 0.44, 0.59)、SB4组0.68(95%CI 0.61, 0.75)。

核心结论

  • 接受依那西普或SB4治疗的类风湿关节炎患者第52周疾病状态与药物持续性结局相似。

研究设计与样本

  • 回顾性数据库研究,纳入挪威5个中心2010至2018年间接受依那西普或SB4治疗且随访≥1年的类风湿关节炎患者1455例,应用EULAR比较效果研究考虑要点。
  • 比较非匹配依那西普队列(n=575)与SB4队列(n=299),并用倾向性评分匹配调整混杂因素后进行匹配分析(两组各n=172)。

主要发现

  • 非匹配分析中,依那西普组(n=221)与SB4组(n=106)第52周DAS28较基线变化差值均值-0.02(95%CI -0.32, 0.27),在预设等效界值±0.6内。
  • 倾向性评分匹配分析中,依那西普组(n=49)与SB4组(n=49)DAS28变化差值为0.03(95%CI -0.46, 0.52),在预设等效界值内。
  • 非匹配分析第52周药物持续性:依那西普组0.62(95%CI 0.57, 0.65),SB4组0.66(95%CI 0.60, 0.71)。
  • 倾向性评分匹配队列第52周药物持续性:依那西普组0.52(95%CI 0.44, 0.59),SB4组0.68(95%CI 0.61, 0.75)。

关键数值与推荐

  • DAS28第52周较基线变化的预设等效界值为±0.6。
  • 非匹配分析依那西普组(n=221)与SB4组(n=106)DAS28变化差值均值-0.02(95%CI -0.32, 0.27),在等效界值内。
  • 倾向性评分匹配分析依那西普组(n=49)与SB4组(n=49)DAS28变化差值0.03(95%CI -0.46, 0.52),在等效界值内。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Biosimilars represent cost-effective alternatives to reference biologic disease-modifying antirheumatic drugs. Our objective was to compare drug effectiveness and drug persistence in the treatment of rheumatoid arthritis (RA), assessing the etanercept biosimilar SB4 in efficacy and safety compared with reference etanercept in a Phase III, randomized controlled trial. We applied EULAR Points to Consider for Comparative Effectiveness Research in a retrospective database study of etanercept and SB4 in patients treated in clinical practice in Norway. METHODS: Patients with RA (n = 1,455) treated with etanercept or SB4 between 2010 and 2018 at 5 centers in Norway with ≥1 year of follow-up were included. Disease outcomes (Disease Activity Score in 28 joints [DAS28] at week 52) and drug persistence were compared between unmatched etanercept (n = 575) and SB4 (n = 299) cohorts and matched analyses (n = 172, both cohorts) using propensity score (PS) matching to adjust for confounders. RESULTS: In unmatched analyses, the difference in change from baseline between etanercept (n = 221) and SB4 (n = 106) for DAS28 at week 52 was mean -0.02 (95% confidence interval [95% CI] -0.32, 0.27), demonstrating equivalence by the predetermined equivalence margin (±0.6). In PS-matched analyses, the difference between etanercept (n = 49) and SB4 (n = 49) was 0.03 (95% CI -0.46, 0.52), within the predefined equivalence margin. Persistence using the drug at week 52 was similar between etanercept (0.62 [95% CI 0.57, 0.65]) and SB4 (0.66 [95% CI 0.60, 0.71]) cohorts in the unmatched analysis; in PS-matched cohorts, persistence at week 52 was 0.52 (95% CI 0.44, 0.59) for etanercept and 0.68 (95% CI 0.61, 0.75) for SB4. CONCLUSION: Outcomes for disease status/drug persistence at week 52 were similar between patients with RA treated with etanercept or SB4.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Haugeberg G, Bakland G, Rødevand E, et al. Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway. Arthritis Care Res (Hoboken). 2023. PMID: 36722450. doi:10.1002/acr.25092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。